Drugs / Vevoctadekin
Vevoctadekin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06588660 | Dec 2024 → Feb 2025 | plasma cell myeloma | University of Washington | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07098364 | Dec 2025 → Oct 2030 | high grade B-cell lymphoma, indolent B-cell non-Hodgkin lymphoma, primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Suspended | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04787042 | Aug 2021 → Jun 2025 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Simcha IL-18, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vevoctadekin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07098364 ↗ |
| Known as | ST-067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04787042 ↗ |
| Known as | Vevoctadekina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314892 ↗ |
| Known as | Vevoctadekine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314892 ↗ |
| Modality | Protein / enzyme biologic | “ST-067 is an engineered variant of human interleukin-18.” NCT04787042 ↗ |
| Route | Subcutaneous | “ST-067 given as an SC injection” NCT04787042 ↗ |